Barclays analyst Glen Santangelo initiated coverage of Doximity (DOCS) with an Overweight rating and $63 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Nvidia resumed, Palo Alto downgraded: Wall Street’s top analyst calls
- Doximity: Strong Growth Potential and Attractive Valuation Amid Share Price Pullback
- Doximity upgraded to Strong Buy from Outperform at Raymond James
- Doximity initiated with a Market Perform at BMO Capital
- OpenAI Is Considering Expanding into Healthcare